<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846088</url>
  </required_header>
  <id_info>
    <org_study_id>BAT2221031</org_study_id>
    <nct_id>NCT04846088</nct_id>
  </id_info>
  <brief_title>A Study to Characterize Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouches in Adult Cigarette Smokers</brief_title>
  <official_title>A Randomized, Crossover Clinical Study to Characterize Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouches in Adult Cigarette Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British American Tobacco (Investments) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British American Tobacco (Investments) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate plasma nicotine pharmacokinetic (PK) parameters following&#xD;
      the use of nicotine pouches in cigarette smokers who have experience with use of smokeless&#xD;
      tobacco (SST) [e.g., snus, moist snuff].&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential subjects will complete screening procedures to assess their eligibility within 45&#xD;
      days prior to enrollment, randomization and confinement.&#xD;
&#xD;
      Following the Screening Visit, eligible subjects will be scheduled for a Day 1 Check-in visit&#xD;
      to complete procedures to confirm eligibility. Eligible subjects will be enrolled and begin&#xD;
      confinement at the clinical site for 10 days and 9 nights. In addition, on Day 1, subjects&#xD;
      will use at least one nicotine pouch (7 mg nicotine) but no more than 3 pouches to&#xD;
      familiarize themselves with the investigational product (IP). Subjects will participate in&#xD;
      separate Test Sessions for plasma nicotine PK assessment, one for each IP. Each Test Session&#xD;
      will last for approximately 3 hours following the start of the IP use, and will include&#xD;
      collection of plasma samples for PK assessments prior to, during, and following IP use.&#xD;
&#xD;
      Safety will be monitored throughout the study by the Principal Investigator (PI) (or&#xD;
      designee) by assessing adverse events (AEs), vital sign measurements, physical examinations&#xD;
      (including an oral examination), and clinical laboratory tests. Mandatory physical and oral&#xD;
      examination will be performed as part of end of study or early termination procedures.&#xD;
&#xD;
      The clinical site will attempt to contact all subjects who used at least one IP (including&#xD;
      subjects who terminate the study early) using their standard procedures approximately 7 days&#xD;
      after the last IP use to determine if any AE has occurred since the last study visit. A&#xD;
      return visit may be scheduled for follow-up assessments at the discretion of the PI or an&#xD;
      appropriately qualified designee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2021</start_date>
  <completion_date type="Anticipated">May 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCnic 0-180 mins</measure>
    <time_frame>0-180 minutes</time_frame>
    <description>Baseline-adjusted area under the plasma nicotine concentration-versus-time curve (AUCnic) from time zero to 180 minutes after the start of IP use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>180 minutes</time_frame>
    <description>Maximum baseline-adjusted plasma concentration of nicotine</description>
  </primary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Tobacco Use</condition>
  <condition>Tobacco Smoking</condition>
  <arm_group>
    <arm_group_label>Product usage order ABICHDGEF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (ABICHDGEF) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order BCADIEHFG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (BCADIEHFG) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order CDBEAFIGH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (CDBEAFIGH) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order DECFBGAHI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (DECFBGAHI) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order EFDGCHBIA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (EFDGCHBIA) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order FGEHDICAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (FGEHDICAB) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order GHFIEADBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (GHFIEADBC) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order HIGAFBECD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (HIGAFBECD) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order IAHBGCFDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (IAHBGCFDE) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order FEGDHCIBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (FEGDHCIBA) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order GFHEIDACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (GFHEIDACB) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order HGIFAEBDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (HGIFAEBDC) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order IHAGBFCED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (IHAGBFCED) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order AIBHCGDFE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (AIBHCGDFE) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order BACIDHEGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (BACIDHEGF) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order CBDAEIFHG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (CBDAEIFHG) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order DCEBFAGIH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (DCEBFAGIH) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order EDFCGBHAI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 9 products (EDFCGBHAI) during a familiarization period, followed by a 3 hour Test Session</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product A</intervention_name>
    <description>A 4mg nicotine pouch product</description>
    <arm_group_label>Product usage order ABICHDGEF</arm_group_label>
    <arm_group_label>Product usage order AIBHCGDFE</arm_group_label>
    <arm_group_label>Product usage order BACIDHEGF</arm_group_label>
    <arm_group_label>Product usage order BCADIEHFG</arm_group_label>
    <arm_group_label>Product usage order CBDAEIFHG</arm_group_label>
    <arm_group_label>Product usage order CDBEAFIGH</arm_group_label>
    <arm_group_label>Product usage order DCEBFAGIH</arm_group_label>
    <arm_group_label>Product usage order DECFBGAHI</arm_group_label>
    <arm_group_label>Product usage order EDFCGBHAI</arm_group_label>
    <arm_group_label>Product usage order EFDGCHBIA</arm_group_label>
    <arm_group_label>Product usage order FEGDHCIBA</arm_group_label>
    <arm_group_label>Product usage order FGEHDICAB</arm_group_label>
    <arm_group_label>Product usage order GFHEIDACB</arm_group_label>
    <arm_group_label>Product usage order GHFIEADBC</arm_group_label>
    <arm_group_label>Product usage order HGIFAEBDC</arm_group_label>
    <arm_group_label>Product usage order HIGAFBECD</arm_group_label>
    <arm_group_label>Product usage order IAHBGCFDE</arm_group_label>
    <arm_group_label>Product usage order IHAGBFCED</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product B</intervention_name>
    <description>A 7mg nicotine pouch product</description>
    <arm_group_label>Product usage order ABICHDGEF</arm_group_label>
    <arm_group_label>Product usage order AIBHCGDFE</arm_group_label>
    <arm_group_label>Product usage order BACIDHEGF</arm_group_label>
    <arm_group_label>Product usage order BCADIEHFG</arm_group_label>
    <arm_group_label>Product usage order CBDAEIFHG</arm_group_label>
    <arm_group_label>Product usage order CDBEAFIGH</arm_group_label>
    <arm_group_label>Product usage order DCEBFAGIH</arm_group_label>
    <arm_group_label>Product usage order DECFBGAHI</arm_group_label>
    <arm_group_label>Product usage order EDFCGBHAI</arm_group_label>
    <arm_group_label>Product usage order EFDGCHBIA</arm_group_label>
    <arm_group_label>Product usage order FEGDHCIBA</arm_group_label>
    <arm_group_label>Product usage order FGEHDICAB</arm_group_label>
    <arm_group_label>Product usage order GFHEIDACB</arm_group_label>
    <arm_group_label>Product usage order GHFIEADBC</arm_group_label>
    <arm_group_label>Product usage order HGIFAEBDC</arm_group_label>
    <arm_group_label>Product usage order HIGAFBECD</arm_group_label>
    <arm_group_label>Product usage order IAHBGCFDE</arm_group_label>
    <arm_group_label>Product usage order IHAGBFCED</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product C</intervention_name>
    <description>A 7mg nicotine pouch product</description>
    <arm_group_label>Product usage order ABICHDGEF</arm_group_label>
    <arm_group_label>Product usage order AIBHCGDFE</arm_group_label>
    <arm_group_label>Product usage order BACIDHEGF</arm_group_label>
    <arm_group_label>Product usage order BCADIEHFG</arm_group_label>
    <arm_group_label>Product usage order CBDAEIFHG</arm_group_label>
    <arm_group_label>Product usage order CDBEAFIGH</arm_group_label>
    <arm_group_label>Product usage order DCEBFAGIH</arm_group_label>
    <arm_group_label>Product usage order DECFBGAHI</arm_group_label>
    <arm_group_label>Product usage order EDFCGBHAI</arm_group_label>
    <arm_group_label>Product usage order EFDGCHBIA</arm_group_label>
    <arm_group_label>Product usage order FEGDHCIBA</arm_group_label>
    <arm_group_label>Product usage order FGEHDICAB</arm_group_label>
    <arm_group_label>Product usage order GFHEIDACB</arm_group_label>
    <arm_group_label>Product usage order GHFIEADBC</arm_group_label>
    <arm_group_label>Product usage order HGIFAEBDC</arm_group_label>
    <arm_group_label>Product usage order HIGAFBECD</arm_group_label>
    <arm_group_label>Product usage order IAHBGCFDE</arm_group_label>
    <arm_group_label>Product usage order IHAGBFCED</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product D</intervention_name>
    <description>A 7mg nicotine pouch product</description>
    <arm_group_label>Product usage order ABICHDGEF</arm_group_label>
    <arm_group_label>Product usage order AIBHCGDFE</arm_group_label>
    <arm_group_label>Product usage order BACIDHEGF</arm_group_label>
    <arm_group_label>Product usage order BCADIEHFG</arm_group_label>
    <arm_group_label>Product usage order CBDAEIFHG</arm_group_label>
    <arm_group_label>Product usage order CDBEAFIGH</arm_group_label>
    <arm_group_label>Product usage order DCEBFAGIH</arm_group_label>
    <arm_group_label>Product usage order DECFBGAHI</arm_group_label>
    <arm_group_label>Product usage order EDFCGBHAI</arm_group_label>
    <arm_group_label>Product usage order EFDGCHBIA</arm_group_label>
    <arm_group_label>Product usage order FEGDHCIBA</arm_group_label>
    <arm_group_label>Product usage order FGEHDICAB</arm_group_label>
    <arm_group_label>Product usage order GFHEIDACB</arm_group_label>
    <arm_group_label>Product usage order GHFIEADBC</arm_group_label>
    <arm_group_label>Product usage order HGIFAEBDC</arm_group_label>
    <arm_group_label>Product usage order HIGAFBECD</arm_group_label>
    <arm_group_label>Product usage order IAHBGCFDE</arm_group_label>
    <arm_group_label>Product usage order IHAGBFCED</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product E</intervention_name>
    <description>A 7mg nicotine pouch product</description>
    <arm_group_label>Product usage order ABICHDGEF</arm_group_label>
    <arm_group_label>Product usage order AIBHCGDFE</arm_group_label>
    <arm_group_label>Product usage order BACIDHEGF</arm_group_label>
    <arm_group_label>Product usage order BCADIEHFG</arm_group_label>
    <arm_group_label>Product usage order CBDAEIFHG</arm_group_label>
    <arm_group_label>Product usage order CDBEAFIGH</arm_group_label>
    <arm_group_label>Product usage order DCEBFAGIH</arm_group_label>
    <arm_group_label>Product usage order DECFBGAHI</arm_group_label>
    <arm_group_label>Product usage order EDFCGBHAI</arm_group_label>
    <arm_group_label>Product usage order EFDGCHBIA</arm_group_label>
    <arm_group_label>Product usage order FEGDHCIBA</arm_group_label>
    <arm_group_label>Product usage order FGEHDICAB</arm_group_label>
    <arm_group_label>Product usage order GFHEIDACB</arm_group_label>
    <arm_group_label>Product usage order GHFIEADBC</arm_group_label>
    <arm_group_label>Product usage order HGIFAEBDC</arm_group_label>
    <arm_group_label>Product usage order HIGAFBECD</arm_group_label>
    <arm_group_label>Product usage order IAHBGCFDE</arm_group_label>
    <arm_group_label>Product usage order IHAGBFCED</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product F</intervention_name>
    <description>A 7mg nicotine pouch product</description>
    <arm_group_label>Product usage order ABICHDGEF</arm_group_label>
    <arm_group_label>Product usage order AIBHCGDFE</arm_group_label>
    <arm_group_label>Product usage order BACIDHEGF</arm_group_label>
    <arm_group_label>Product usage order BCADIEHFG</arm_group_label>
    <arm_group_label>Product usage order CBDAEIFHG</arm_group_label>
    <arm_group_label>Product usage order CDBEAFIGH</arm_group_label>
    <arm_group_label>Product usage order DCEBFAGIH</arm_group_label>
    <arm_group_label>Product usage order DECFBGAHI</arm_group_label>
    <arm_group_label>Product usage order EDFCGBHAI</arm_group_label>
    <arm_group_label>Product usage order EFDGCHBIA</arm_group_label>
    <arm_group_label>Product usage order FEGDHCIBA</arm_group_label>
    <arm_group_label>Product usage order FGEHDICAB</arm_group_label>
    <arm_group_label>Product usage order GFHEIDACB</arm_group_label>
    <arm_group_label>Product usage order GHFIEADBC</arm_group_label>
    <arm_group_label>Product usage order HGIFAEBDC</arm_group_label>
    <arm_group_label>Product usage order HIGAFBECD</arm_group_label>
    <arm_group_label>Product usage order IAHBGCFDE</arm_group_label>
    <arm_group_label>Product usage order IHAGBFCED</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product G</intervention_name>
    <description>A 7mg nicotine pouch product</description>
    <arm_group_label>Product usage order ABICHDGEF</arm_group_label>
    <arm_group_label>Product usage order AIBHCGDFE</arm_group_label>
    <arm_group_label>Product usage order BACIDHEGF</arm_group_label>
    <arm_group_label>Product usage order BCADIEHFG</arm_group_label>
    <arm_group_label>Product usage order CBDAEIFHG</arm_group_label>
    <arm_group_label>Product usage order CDBEAFIGH</arm_group_label>
    <arm_group_label>Product usage order DCEBFAGIH</arm_group_label>
    <arm_group_label>Product usage order DECFBGAHI</arm_group_label>
    <arm_group_label>Product usage order EDFCGBHAI</arm_group_label>
    <arm_group_label>Product usage order EFDGCHBIA</arm_group_label>
    <arm_group_label>Product usage order FEGDHCIBA</arm_group_label>
    <arm_group_label>Product usage order FGEHDICAB</arm_group_label>
    <arm_group_label>Product usage order GFHEIDACB</arm_group_label>
    <arm_group_label>Product usage order GHFIEADBC</arm_group_label>
    <arm_group_label>Product usage order HGIFAEBDC</arm_group_label>
    <arm_group_label>Product usage order HIGAFBECD</arm_group_label>
    <arm_group_label>Product usage order IAHBGCFDE</arm_group_label>
    <arm_group_label>Product usage order IHAGBFCED</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product H</intervention_name>
    <description>A 7mg nicotine pouch product</description>
    <arm_group_label>Product usage order ABICHDGEF</arm_group_label>
    <arm_group_label>Product usage order AIBHCGDFE</arm_group_label>
    <arm_group_label>Product usage order BACIDHEGF</arm_group_label>
    <arm_group_label>Product usage order BCADIEHFG</arm_group_label>
    <arm_group_label>Product usage order CBDAEIFHG</arm_group_label>
    <arm_group_label>Product usage order CDBEAFIGH</arm_group_label>
    <arm_group_label>Product usage order DCEBFAGIH</arm_group_label>
    <arm_group_label>Product usage order DECFBGAHI</arm_group_label>
    <arm_group_label>Product usage order EDFCGBHAI</arm_group_label>
    <arm_group_label>Product usage order EFDGCHBIA</arm_group_label>
    <arm_group_label>Product usage order FEGDHCIBA</arm_group_label>
    <arm_group_label>Product usage order FGEHDICAB</arm_group_label>
    <arm_group_label>Product usage order GFHEIDACB</arm_group_label>
    <arm_group_label>Product usage order GHFIEADBC</arm_group_label>
    <arm_group_label>Product usage order HGIFAEBDC</arm_group_label>
    <arm_group_label>Product usage order HIGAFBECD</arm_group_label>
    <arm_group_label>Product usage order IAHBGCFDE</arm_group_label>
    <arm_group_label>Product usage order IHAGBFCED</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product I</intervention_name>
    <description>A 7mg nicotine pouch product</description>
    <arm_group_label>Product usage order ABICHDGEF</arm_group_label>
    <arm_group_label>Product usage order AIBHCGDFE</arm_group_label>
    <arm_group_label>Product usage order BACIDHEGF</arm_group_label>
    <arm_group_label>Product usage order BCADIEHFG</arm_group_label>
    <arm_group_label>Product usage order CBDAEIFHG</arm_group_label>
    <arm_group_label>Product usage order CDBEAFIGH</arm_group_label>
    <arm_group_label>Product usage order DCEBFAGIH</arm_group_label>
    <arm_group_label>Product usage order DECFBGAHI</arm_group_label>
    <arm_group_label>Product usage order EDFCGBHAI</arm_group_label>
    <arm_group_label>Product usage order EFDGCHBIA</arm_group_label>
    <arm_group_label>Product usage order FEGDHCIBA</arm_group_label>
    <arm_group_label>Product usage order FGEHDICAB</arm_group_label>
    <arm_group_label>Product usage order GFHEIDACB</arm_group_label>
    <arm_group_label>Product usage order GHFIEADBC</arm_group_label>
    <arm_group_label>Product usage order HGIFAEBDC</arm_group_label>
    <arm_group_label>Product usage order HIGAFBECD</arm_group_label>
    <arm_group_label>Product usage order IAHBGCFDE</arm_group_label>
    <arm_group_label>Product usage order IHAGBFCED</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to read, understand, and willing to sign an informed consent form (ICF) and&#xD;
             complete the questionnaire written in English.&#xD;
&#xD;
          2. Generally healthy males or females, 22 to 65 years of age, inclusive, at the time of&#xD;
             consent.&#xD;
&#xD;
          3. Body mass index (BMI) within 18.0 to 40.0 kg/m2, inclusive (minimum weight of at least&#xD;
             50.0 kg) at Screening.&#xD;
&#xD;
          4. Healthy, as determined by no clinically significant medical history, physical&#xD;
             examination, 12-lead ECG, vital signs, or laboratory (including hematology, clinical&#xD;
             chemistry, urinalysis, and serology) findings at Screening, as judged by the PI or&#xD;
             designee.&#xD;
&#xD;
          5. Smoke combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in&#xD;
             length as the primary source of tobacco use.&#xD;
&#xD;
          6. Self-reported use of smokeless tobacco (ST) products (e.g., moist snuff, snus) at&#xD;
             least 1 to 2 times in the subject's lifetime prior to screening.&#xD;
&#xD;
          7. Smokes an average of at least 10 cigarettes per day (CPD) and inhale the smoke, for at&#xD;
             least 1 year prior to Screening. Brief periods of abstinence due to illness, quit&#xD;
             attempt (prior to 30 days of Screening), or clinical study participation (prior to 30&#xD;
             days of Screening) will be allowed at the discretion of the PI or designee.&#xD;
&#xD;
          8. Agrees to smoke the same usual brand (UB) cigarette throughout the study period. The&#xD;
             UB cigarette is defined as the reported cigarette brand and style currently smoked&#xD;
             most frequently by the subject.&#xD;
&#xD;
          9. Expired breath carbon monoxide (ECO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and&#xD;
             at Check-in.&#xD;
&#xD;
         10. Positive urine cotinine test (≥ 200 ng/mL) at Screening.&#xD;
&#xD;
         11. Willing to use the IPs during the study period.&#xD;
&#xD;
         12. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to start&#xD;
             of each of nine Test Sessions.&#xD;
&#xD;
         13. If female and of non-childbearing potential, must meet one of the following criteria:&#xD;
&#xD;
               1. Surgically sterile (i.e., has undergone complete hysterectomy, bilateral&#xD;
                  oophorectomy, or tubal ligation/occlusion); or&#xD;
&#xD;
               2. In a menopausal state (at least 1 year without menses), as confirmed by follicle&#xD;
                  stimulating hormone levels (≥ 40 mIU/mL).&#xD;
&#xD;
         14. If female and of childbearing potential, must agree to use one of the accepted&#xD;
             contraceptive regimens from at least 30 days prior to the first administration of the&#xD;
             IP during the study, and for at least 30 days after the last dose of the study&#xD;
             medication. An acceptable method of contraception includes one of the following:&#xD;
&#xD;
               1. Abstinence from heterosexual intercourse;&#xD;
&#xD;
               2. Non-hormonal releasing intrauterine device;&#xD;
&#xD;
               3. Use of a double barrier method (e.g., condom and spermicide) during the study and&#xD;
                  for at least 30 days after the last dose of the study medication;&#xD;
&#xD;
               4. For females of &lt; 35 years old only: Hormonal releasing intrauterine device; or&#xD;
&#xD;
               5. For females of &lt; 35 years old only: Hormonal contraceptives (e.g.,&#xD;
                  oral/transdermal patch/injectable/implant hormonal birth control products).&#xD;
&#xD;
         15. Agrees to an in-clinic confinement of at least 10 days (9 nights).&#xD;
&#xD;
         16. Must be willing to comply with the requirements and restrictions of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to tolerate at least one 7 mg nicotine pouch for at least 45 minutes during&#xD;
             the Product Familiarization Period at Check-in.&#xD;
&#xD;
          2. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal,&#xD;
             hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological&#xD;
             disease, or any other concurrent disease or medical condition that, in the opinion of&#xD;
             the PI or designee, makes the study subject unsuitable to participate in this clinical&#xD;
             study.&#xD;
&#xD;
          3. History, presence of, or clinical laboratory test results indicating diabetes.&#xD;
&#xD;
          4. Scheduled treatment for asthma currently or within the past consecutive 12 months&#xD;
             prior to the Screening Visit. As-needed treatment, such as inhalers, may be included&#xD;
             at the PI or designee discretion pending approval from the Medical Monitor.&#xD;
&#xD;
          5. History or presence of bleeding or clotting disorders.&#xD;
&#xD;
          6. Presence of gum bleeding and/or abscess, open mouth sores or oral ulcers at Screening&#xD;
             or Check-in.&#xD;
&#xD;
          7. Any history of cancer, except for primary cancers of skin such as localized basal&#xD;
             cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.&#xD;
&#xD;
          8. Clinically significant abnormal findings on the vital signs, physical and oral&#xD;
             examinations, medical history, or clinical laboratory results, in the opinion of the&#xD;
             PI or designee.&#xD;
&#xD;
          9. Systolic blood pressure of &gt; 160 mmHg or a diastolic blood pressure of &gt; 95 mmHg,&#xD;
             measured after being seated for five minutes at Screening and at Check-in.&#xD;
&#xD;
         10. History of severe allergic reaction (including anaphylaxis) to any substance, previous&#xD;
             status asthmaticus, food allergies/intolerances/restrictions (including mint,&#xD;
             wintergreen or spearmint flavoring), or special dietary needs which, in the judgment&#xD;
             of the PI or designee, would contraindicate the subject's participation in the study.&#xD;
&#xD;
         11. Requires concomitant treatment with prescription or non-prescription products that&#xD;
             contain pseudoephedrine (e.g., nasal/sinus decongestants).&#xD;
&#xD;
         12. Has used medications known to interact with cytochrome P450 2A6 (including, but not&#xD;
             limited to, amiodarone, desipramine, isoniazid, ketoconazole, miconazole,&#xD;
             phenobarbital, rifampin, tranylcypromine, methoxsalen) within (≤) 3 months prior to&#xD;
             Check-in and throughout the study.&#xD;
&#xD;
         13. Hemoglobin level is &lt; 12.5 g/dL for females or &lt; 13.0 g/dL for males at Screening.&#xD;
&#xD;
         14. Females who, at Screening or Check-in, have a positive pregnancy test, are pregnant,&#xD;
             breastfeeding, or intend to become pregnant during the course of the study.&#xD;
&#xD;
         15. A positive urine drug screen without evidence of prescribed corresponding concomitant&#xD;
             medication(s) at Screening or Check-in.&#xD;
&#xD;
         16. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C virus (HCV) at Screening.&#xD;
&#xD;
         17. Self-reported use of any the study IP currently or in the past.&#xD;
&#xD;
         18. Current, regular user (i.e., &gt; 5 times per month) of any tobacco products other than&#xD;
             combustible cigarettes or ST within (≤) 6 months prior to screening.&#xD;
&#xD;
         19. Use of any medication or substance that aids in smoking cessation, including but not&#xD;
             limited to any nicotine replacement therapy (e.g., nicotine gum, lozenge, patch),&#xD;
             varenicline (Chantix®), bupropion Wellbutrin®, Zyban®), or lobelia extract within (≤)&#xD;
             30 days prior to the signing of informed consent.&#xD;
&#xD;
         20. Postpones a decision to quit using tobacco- or nicotine-containing products in order&#xD;
             to participate in this study or self-reports a previous attempt within (≤) 30 days&#xD;
             prior to the signing the informed consent.&#xD;
&#xD;
         21. Any use of aspirin (≥ 325 mg/day) or anticoagulants within (≤) 30 days prior to the&#xD;
             signing the informed consent.&#xD;
&#xD;
         22. Individuals ≥ 35 years of age currently using systemic, estrogen-containing&#xD;
             contraception or hormone replacement therapy within (≤) 30 days prior to the signing&#xD;
             the informed consent.&#xD;
&#xD;
         23. Whole blood donation within (≤) 8 weeks (≤ 56 days) prior to the signing of informed&#xD;
             consent and between Screening and Check-in.&#xD;
&#xD;
         24. Plasma donation within (≤) 7 days prior to the signing of informed consent and between&#xD;
             Screening and Check-in.&#xD;
&#xD;
         25. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or&#xD;
             nicotine-containing products as part of their job.&#xD;
&#xD;
         26. Participation in another clinical trial within (≤) 30 days prior to the signing of&#xD;
             informed consent. The 30-day window for each subject will be derived from the date of&#xD;
             the last study event in the previous study to the time of signing of informed consent&#xD;
             in the current study.&#xD;
&#xD;
         27. History of drug or alcohol dependence within (≤)24 months prior to Screening.&#xD;
&#xD;
         28. Drinks more than 21 servings of alcoholic beverages per week or has a positive alcohol&#xD;
             result at Screening or Check-in.&#xD;
&#xD;
         29. Determined by the PI or designee to be inappropriate for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Kelsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altasciences Clinical Kansas, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mike McEwan</last_name>
    <phone>07720148248</phone>
    <email>Mike_McEwan@bat.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Altasciences Clinical Kansas, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Debra Kelsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

